Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer
Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer
Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer